🇺🇸 FDA
Pipeline program

GSK3196165 Dose 1

201789

Phase 2 small_molecule completed

Quick answer

GSK3196165 Dose 1 for Arthritis, Rheumatoid is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline
Indication
Arthritis, Rheumatoid
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials